Αρχική World News iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive,... World News iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer Από Ogkologos - 14 Νοεμβρίου, 2024 958 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Όροι χρήσης και προϋποθέσεις 18 Ιανουαρίου, 2019 Should People Over Age 75 Be Screened for Colorectal Cancer? 15 Ιουνίου, 2021 Airline Won’t Let Dad And Newborn On Plane, So Kind Stranger... 19 Φεβρουαρίου, 2020 ALK Mutations and Amplifications are Independent Predictors of Poorer Survival in... 24 Ιουνίου, 2021 Φόρτωση περισσοτέρων HOT NEWS OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and... FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk... News digest – HPV vaccine, 1 million breast screenings missed and... Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively...